JP2021526845A5 - - Google Patents

Info

Publication number
JP2021526845A5
JP2021526845A5 JP2021500908A JP2021500908A JP2021526845A5 JP 2021526845 A5 JP2021526845 A5 JP 2021526845A5 JP 2021500908 A JP2021500908 A JP 2021500908A JP 2021500908 A JP2021500908 A JP 2021500908A JP 2021526845 A5 JP2021526845 A5 JP 2021526845A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
pharmaceutical composition
sequence described
Prior art date
Application number
JP2021500908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526845A (ja
JP7534281B2 (ja
JPWO2020012038A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/069035 external-priority patent/WO2020012038A1/en
Publication of JP2021526845A publication Critical patent/JP2021526845A/ja
Publication of JP2021526845A5 publication Critical patent/JP2021526845A5/ja
Publication of JPWO2020012038A5 publication Critical patent/JPWO2020012038A5/ja
Priority to JP2024125676A priority Critical patent/JP2024160275A/ja
Application granted granted Critical
Publication of JP7534281B2 publication Critical patent/JP7534281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500908A 2018-07-13 2019-07-15 Cd38抗体を使用したトロゴサイトーシスを介した治療 Active JP7534281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125676A JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862697719P 2018-07-13 2018-07-13
US62/697,719 2018-07-13
US201962848861P 2019-05-16 2019-05-16
US62/848,861 2019-05-16
PCT/EP2019/069035 WO2020012038A1 (en) 2018-07-13 2019-07-15 Trogocytosis-mediated therapy using cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125676A Division JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Publications (4)

Publication Number Publication Date
JP2021526845A JP2021526845A (ja) 2021-10-11
JP2021526845A5 true JP2021526845A5 (https=) 2022-07-21
JPWO2020012038A5 JPWO2020012038A5 (https=) 2022-07-21
JP7534281B2 JP7534281B2 (ja) 2024-08-14

Family

ID=67441085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500908A Active JP7534281B2 (ja) 2018-07-13 2019-07-15 Cd38抗体を使用したトロゴサイトーシスを介した治療
JP2024125676A Pending JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125676A Pending JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Country Status (5)

Country Link
US (1) US20240254252A1 (https=)
EP (1) EP3820890A1 (https=)
JP (2) JP7534281B2 (https=)
MA (1) MA53123A (https=)
WO (1) WO2020012038A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220130724A (ko) * 2020-01-16 2022-09-27 젠맵 에이/에스 Cd38 항체의 제제 및 그의 용도
KR20230018439A (ko) * 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
JP2025510415A (ja) * 2022-03-28 2025-04-14 ヴァイジェン-バイオ,インコーポレイテッド 養子細胞療法用の遺伝的に操作された抗体抵抗性(gear)細胞
US20250382378A1 (en) 2022-10-31 2025-12-18 Genmab A/S Cd38 antibodies and uses thereof
US20250296989A1 (en) * 2024-03-20 2025-09-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック,インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価fcガンマ受容体結合活性を有する分子
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
DK2970456T3 (da) 2013-03-14 2021-07-05 Translate Bio Inc Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
US10130649B2 (en) 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
CN106255704A (zh) 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
EP3397613A1 (en) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN109563511A (zh) 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
WO2018114877A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
EP3559250A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
MX2019006123A (es) 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery

Similar Documents

Publication Publication Date Title
US11498963B2 (en) Anti-LILRB antibodies and their use in detecting and treating cancer
JP2021524276A5 (https=)
JP2021526845A5 (https=)
Adler et al. Therapeutic antibodies against cancer
KR101843807B1 (ko) 암의 치료 및/또는 예방을 위한 의약품
CA2788545C (en) Pharmaceutical composition for treating and/or preventing cancer
JP7753186B2 (ja) 抗pd-1抗体およびその医学的使用
KR102115143B1 (ko) 항 fgfr2 항체
BR112019007714B1 (pt) Anticorpos anti-4-1bb, uso do mesmo, composição farmacêutica, métodos para determinar uma dose, para aumentar a secreção de ifn-gama por uma célula in vitro e para proliferação ex vivo ou isolamento de células t ativadas e uso das mesmas
HUE030103T2 (en) A pharmaceutical composition for the treatment and / or prevention of cancer
JP2022525071A (ja) Ctla-4遮断剤とpd-1遮断剤とを含む抗癌併用療法
TW201642897A (zh) Her2結合劑治療
JP2019151635A (ja) 抗fgfr2抗体と他剤の組合せ
CN115135344A (zh) 在疗法中使用的抗体
WO2022179507A1 (en) Methods of preventing, alleviating or treating tumors
AU2021378152A1 (en) COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
JP2023089273A (ja) 自己免疫疾患治療用抗体
JPWO2020012036A5 (https=)
CN112041346B (zh) 用于与抗pd-1抗体组合的抗cd137抗体
Wu et al. Development and characterization of 4A7: a high-affinity monoclonal antibody targeting Claudin18. 2
JPWO2020012038A5 (https=)
CN114616245B (zh) 一种抗cd38的抗体及其用途
JP2020507576A (ja) Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP4523702A1 (en) Combination of antibody-drug conjugate and anti-sirpalpha antibody
JP7384668B2 (ja) 細胞傷害性t細胞枯渇用組成物